Home / Stocks / Indo Us Biotech Ltd
INDOUS

Indo Us Biotech Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹66.46

Change

+1.44 (2.21%)

Open

₹64.7

Prev. Close

₹65.02

Day High

₹66.9

Day Low

₹64.7

Volume Analysis

Traded

1,682

Delivered

1,528

Delivery %

90.84%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year EPS growth (24.4%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹69.54 ₹68.22 ₹67.34 ₹66.02 ₹65.14 ₹63.82 ₹62.94
Fibonacci ₹68.22 ₹67.38 ₹66.86 ₹66.02 ₹65.18 ₹64.66 ₹63.82
Camarilla ₹67.07 ₹66.86 ₹66.66 ₹66.02 ₹66.26 ₹66.06 ₹65.86

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-44.85%

1 Week

-0.89%

1 Month

-0.58%

3 Months

-22.32%

6 Months

-34.17%

1 Year

-46.67%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹26.08

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

26.07%

Net margin 10.24% × asset turnover 1.48x × equity multiplier 1.72x

Company Overview

Sector

Fast Moving Consumer Goods

Market Cap

₹136 Cr

P/E (TTM)

26.8

ROE

16.9%

Book Value

₹21.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Indo Us Biotech Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Fast Moving Consumer Goods sector, at 53/100. The strongest factor is Financial Strength (98/100), while Momentum (9/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling. Strong 3-year EPS growth (24.4%).

TopFund Score — Fundamentals Quality

53/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

98

Growth

83

Valuation

47

Cash Flow

13

Corporate Governance

43

Momentum

9

Institutional Ownership

30

Business Quality

67

Risk & Volatility

30

Liquidity

50

From Screener.in

  • +Debtor days have improved from 191 to 152 days.
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Tax rate seems low
  • −Company has high debtors of 152 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication Unaudited Financial Results for the quarter ended on 30-09-2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 16 22 16 25 22 24 33 31 31 23 26 33 15
Expenses + 13 18 15 21 17 18 29 25 27 19 23 29 18
Operating Profit 3 4 1 4 5 6 5 5 4 4 3 4 -3
OPM % 16.45% 19.13% 6.21% 14.93% 23.09% 23.51% 13.72% 17.78% 13.48% 18.2% 12.41% 12.03% -17.34%
Other Income + 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 1 0 0 0 0 1 1 1 1
Depreciation 0 0 0 0 0 0 1 0 0 0 0 0 0
Profit before tax 2 4 1 3 4 5 4 5 4 3 2 3 -4
Tax % 15.66% 1.87% 17.46% 0.63% 2.03% -0.8% 4.9% 2.49% 3.09% 5.36% 17.23% 1.3% 0.55%
Net Profit + 2 4 1 3 4 5 4 5 3 3 2 3 -4
EPS in Rs 1 2 0 2 2 3 2 2 2 2 1 2 -2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 15 43 -13 29 40 7 112 24 39 -3 -22 7 -51

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022
Sales + 20 19 24 29 35 40 39 49
Expenses + 19 19 23 27 32 36 34 43
Operating Profit 1 1 1 3 3 4 5 7
OPM % 3.06% 2.63% 5.11% 9.22% 9.73% 10.01% 13.58% 13.75%
Other Income + 0 0 0 0 0 0 0 0
Interest 0 0 1 1 0 1 1 1
Depreciation 0 0 0 0 0 0 0 0
Profit before tax 0 0 1 2 3 3 4 5
Tax % -92.31% -50.0% 25.0% 28.92% 25.53% 11.54% -24.68% 4.71%
Net Profit + 1 0 0 1 2 3 5 5
EPS in Rs 0 0 0 1 1 2 3 3
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth 33 -3 28 21 20 — -1 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022
Reserves 1 2 2 2 9 10 15 29
Borrowings + 2 5 5 7 6 9 12 13
Other Liabilities + 3 6 4 6 4 10 11 4
Total Liabilities 8 14 13 17 24 35 44 56
Fixed Assets + 1 1 1 2 1 1 2 6
CWIP 0 0 0 0 1 1 2 2
Investments 0 0 0 0 0 0 0 0
Other Assets + 7 13 11 16 21 32 39 48
Total Assets 8 14 13 17 24 35 44 56
Equity Capital 1 1 1 3 5 6 6 9

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 Mar 2021 Mar 2022
Cash from Operating Activity + — — 0 -1 -3 -1 0 3
Cash from Investing Activity + — — 0 0 -3 -1 -2 -5
Cash from Financing Activity + — — 0 1 6 2 2 3
Net Cash Flow — — 0 0 0 0 0 0
Free Cash Flow — — 0 -1 -4 -1 -2 -1
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — — 11 -16 -92 -20 6 46

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.17% → 68.29%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 29.83% 29.83% 29.82% 29.83% 29.82% 29.83% 29.83% 29.83% 29.83% 31.53% 31.7% 31.46%
Promoters 70.17% 70.18% 70.18% 70.18% 70.18% 70.18% 70.18% 70.18% 70.18% 68.29% 68.29% 68.29%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.18% 0.01% 0.01%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.25%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Fast Moving Consumer Goods — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Indo Us Biotech Ltd (this stock) 136 26.8 3.18 16.9%
B & A Ltd. 131 506.0 0.8 -2.85%
Mangalam Seeds Ltd. 152 10.3 1.6 9.79%
Dhunseri Tea & Ind. Ltd. 158 — 0.29 -2.33%
Shreeoswal S And Che Ltd 112 9.13 2.19 15.4%
Ganges Securities Limited 110 27.7 0.17 0.44%
The Grob Tea Company Ltd 106 — 0.92 —

Which Mutual Funds Hold Indo Us Biotech Ltd?

Frequently Asked Questions about Indo Us Biotech Ltd

Community Sentiment

What are other investors saying about Indo Us Biotech Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.